Recognized as centre of excellence for Biomarker studies, our platform enables you to identify, measure and understand the involvement of your target or biomarker in any biological process.
- Protein Profiling: Up to 6000 targets (based on antibody Array technology)
- Protein Quantification: Up to 1200 targets (based on antibody Array technology)
- Biostatistics analysis solutions
- Compatible with all type of samples (Cells – Pellets - Tissues – Biological fluids …)
Accelerate your understanding of the Secretome/Metabolic signalling pathway…
Gain time by outsourcing part or all of your project
We'll accompany you from R&D to clinical trial projects
Be assured of the quality of data
Combine your Biomarker project with our other service platforms to build & study your own model
Discover some Biomarker case studies
Evaluating the impact of key cell-culture parameter modulation on the predictivity for the identification of specific inhibitors and biomarkers on cancer models
Our customer needed to investigate whether modulating key culture parameters could improve the predictivity of their colorectal cancer cell-based methodology used to select CDK8 inhibitors and/or identify biomarkers.
We performed comparative analysis for them, which involved developing two HT-29 colorectal cancer models: as monolayers in a conventional incubator and as 3D spheroids under physioxia, in the presence/absence of gamma-interferon.
On each model, a viability assay was performed after 3 days incubation time with inhibitors, followed by large-scale proteome profiling analysis on 2000 targets from each cell lysates.
Development of cost effective and robust 3D Colorectal Cancer models for physiological drug response analysis
Our customer needed to obtain in-vivo like responses to drug treatment, through monitoring parameters such as gene expression, biomarker analysis, cellular viability, invasion capability.
We established and implemented a physiologically relevant 3D Colorectal cancer cell-based assay. To answer questions related to variations at transcription and protein level, our methodology required long-term imaging at controlled temperature and gas levels (CO2 and O2), on both 3D cellular models and patient-derived samples. Impact of an anti-cancerous drug was investigated on colon cell lines (HT-29, HCT116 and LS174T) in conventional 2D monolayer and 3D spheroid cultures, in hypoxia or normoxia. Methods used were metastatic invasion assay, gene expression analysis by RT-PCR on hypoxic response and oncopathway genes, and large-scale protein profiling to detect proteomic levels of metalloproteinases and surface proteins known to be involved in colorectal cancer invasion.